Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25383095 | 0.86 | LMNA (0.50) | LMNAPTGS2CA1CA2CA9 | |
| SCHEMBL72014 | 0.84 | KCNH2 (0.55) | LMNAPTGS2DRD2DRD4DRD3 | |
| SCHEMBL28180225 | 0.83 | MAPT (0.54) | LMNAPTGS2DRD2DRD4DRD3 | |
| SCHEMBL8746688 | 0.83 | LMNA (0.58) | LMNAPTGS2CA1CA2CA9 | |
| SCHEMBL6228523 | 0.83 | MAPT (0.65) | LMNAPTGS2DRD2DRD4DRD3 | |
| SCHEMBL7475821 | 0.82 | DRD2 (0.58) | PTGS2DRD2DRD4DRD3KCNH2 | |
| SCHEMBL367677 | 0.81 | HRH3 (0.57) | LMNADRD2DRD4DRD3KCNH2 | |
| SCHEMBL28049501 | 0.81 | LMNA (0.56) | LMNAPTGS2CA1CA2CA9 | |
| SCHEMBL9570575 | 0.81 | DRD2 (0.65) | LMNAPTGS2DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL10553766 | 0.81 | LMNA (0.56) | LMNAPTGS2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106146408-A | The preparation method of 2,5,6 substituted pyrimidines ketone derivatives and the application as anti-hepatic-B virus medicine thereof | 北京大学 | 2016-11-23 | — | — | CN | claimed |
| US-7956050-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-06-07 | — | — | US | claimed |
| CN-101495184-A | Aryl and heteroaryl substituted tetrahydrobenzazepine and its use to block reuptake of norepinephrine dopamine and serotonin | AMR TECHNOLOGY INC (US) | 2009-07-29 | — | — | CN | claimed |
| US-20090118260-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | US | claimed |
| US-20080207595-A9 | Psychological disorders; analgesics; hyperactivity; eating disorders | AMR TECHNOLOGY, INC. (US) | 2008-08-28 | — | — | US | claimed |
| EP-1904069-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| US-7312337-B2 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-7268235-B2 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | claimed |
| US-20070021408-A1 | Psychological disorders; analgesics; eating disorders; drug abuse | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | US | claimed |
| WO-2007011820-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | claimed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | claimed |
| US-4689411-A | ANTIBIOTICS | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1987-08-25 | — | — | US | claimed |
| US-4603014-A | Thiazolinoazetidinone derivatives and process for the preparation of the same | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1986-07-29 | — | — | US | claimed |
| US-3985726-A | DYEING AND PRINTING LEATHER, WOOL, SILK AND SYNTHETIC FIBERS | CIBA-GEIGY AG (CH) | 1976-10-12 | — | — | US | claimed |
| US-3971740-A | DYES FOR POLYESTER FIBERS | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | claimed |
| JP-61212532-A | — | — | None | — | — | JP | disclosed |
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| US-3945989-A | Fluoro triazine containing water insoluble azo dyestuff | CIBA-GEIGY AG (CH) | 1976-03-23 | — | — | US | disclosed |
| US-3943120-A | WATER INSOLUBLE | CIBA-GEIGY AG (CH) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207595-A9 | Psychological disorders; analgesics; hyperactivity; eating disorders | OPRL1, HTR1B, HTR3C | LMNA 3305/4885PTGS2 3186/4885CA1 3659/4885 |
| US-20070021408-A1 | Psychological disorders; analgesics; eating disorders; drug abuse | OPRD1, OPRK1, OPRL1 | LMNA 2543/4885PTGS2 2919/4885CA1 3862/4885 |
| US-20060069262-A1 | Oxadiazoles and their manufacture | OXA1L, CYP1B1, OXER1 | LMNA 4588/4885PTGS2 1451/4885CA1 3779/4885 |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | KCNH1, KCNJ2, KCNH2 | LMNA 2267/4885PTGS2 337/4885CA1 3101/4885 |
| US-20090118260-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, ADRA2C, HTR2B | LMNA 2163/4885PTGS2 3919/4885CA1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.